top of page
  • Recruiting

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM

Updated: May 25, 2022


NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies


Zimberelimab

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies


This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.


Sponsor

Arcus Biosciences, Inc


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04772989


Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

First Posted : February 26, 2021